Antioxidant Treatment of Type 2 Diabetes

Status

Completed

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00609102

Enrollment

Registered

2008-02-06

Start date

2008-07-31

Completion date

2013-09-30

Last updated

2014-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Keywords

Type 2 diabetes

Brief summary

This study examines whether an antioxidant taken orally will improve glucose tolerance and insulin secretion in type 2 diabetic subjects.

Interventions

DRUGPlacebo

one capsule BID

DRUGn-aceylcysteine

450 mgm BID

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

Subjects with a known diagnosis of type 2 diabetes -

Exclusion criteria

None, except known intolerance to n-acetylcysteine \-

Design outcomes

Primary

Measure	Time frame
Blood glucose	3 months

Secondary

Measure	Time frame
HbA1c levels	3 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026